Tier 2 — strong

Acute effects of quercetin-3-O-glucoside on endothelial function and blood pressure: a randomized dose-response study

Nicola P Bondonno, Catherine P Bondonno, Lisa Rich, Emilie Mas, Sujata Shinde, Natalie C Ward, Jonathan M Hodgson, Kevin D Croft
The American journal of clinical nutrition 2016 104(1):97

Bibliography

PubMed
PMID 27169837
DOI
10.3945/ajcn.116.131268
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized controlled acute dose-response crossover study
ModelHuman intervention research
Sample15 healthy volunteers
InterventionQuercetin-3-O-glucoside 0, 50, 100, 200 or 400 mg
DurationFive visits with at least 1-week washouts; acute testing
EndpointsBlood pressure; Exposure and pharmacokinetics

What the study showed, in plain terms

Published in 2016, this source examined cardiovascular and metabolic health. Design: Randomized controlled acute dose-response crossover study. Sample/model: 15 healthy volunteers. The exposure or intervention was Quercetin-3-O-glucoside 0, 50, 100, 200 or 400 mg. Follow-up or treatment period: Five visits with at least 1-week washouts; acute testing.

Metabolite exposure rose with dose, but endothelial function, blood pressure and nitric-oxide measures did not improve.

Acute glycoside dosing in healthy people. Increased blood exposure did not translate into the measured vascular benefit.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Metabolite exposure rose with dose, but endothelial function, blood pressure and nitric-oxide measures did not improve.
  • The recorded outcome domains were Blood pressure; Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin-3-O-glucoside 0, 50, 100, 200 or 400 mg; Five visits with at least 1-week washouts; acute testing.

What this study can and cannot tell us

  • Acute glycoside dosing in healthy people. Increased blood exposure did not translate into the measured vascular benefit.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology